US biopharmaceutical company Alfacell says that, for the first quarter of its 2008 fiscal year, its net loss was $2.7 million, or $0.06 per basic share, up $300,000 on the comparable year-earlier period. The New Jersey-headquartered firm said that the moderate increase was due to higher general and administrative expenses and a drop in investment income.
Alfacell also reported that, as of October 31, it had cash and cash equivalents of approximately $5.4 million, down around $1.6 million from the start of fiscal 2008. The company added that it believes this is sufficient to fund its activities through the first quarter of fiscal 2009, based on current spending rates.
Oncanase development remains on track
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze